Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of daratumumab in combination with bortezomib and dexamethasone in newly diagnosed multiple myeloma
KCT0005839Phase 2Not yet recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of daratumumab in multiple myeloma (MM), sponsored by Janssen Pharmaceutical. Planned start Feb 2021; status: not yet recruiting.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on KCT0005839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0005839.